Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials
Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of an investigational off-the-shelf neoantigen-based cancer i
<p>Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of an investigational off-the-shelf neoantigen-based cancer i</p>